Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "SEC"

3011 News Found

Moraine appointed as distributor for OTSAW’s Hospital robots in Japan
Medical Device | November 12, 2025

Moraine appointed as distributor for OTSAW’s Hospital robots in Japan

Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics


Samsung Epis launches new biotech subsidiary Epis NexLab
Biotech | November 12, 2025

Samsung Epis launches new biotech subsidiary Epis NexLab

The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms


Mount Sinai to implement Microsoft Dragon Copilot for clinical documentation
Digitisation | November 11, 2025

Mount Sinai to implement Microsoft Dragon Copilot for clinical documentation

Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly


CereCore joins oracle partner network to strengthen healthcare IT and EHR services
Digitisation | November 11, 2025

CereCore joins oracle partner network to strengthen healthcare IT and EHR services

The partnership aligns with the launch of Oracle Health’s next-generation electronic health record


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy


Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial
Clinical Trials | November 10, 2025

Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial

While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage


Johnson & Johnson gets FDA nod for new depression treatment
Drug Approval | November 10, 2025

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials


Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
News | November 10, 2025

Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr

Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives


Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Clinical Trials | November 10, 2025

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026